Alcoholic Hepatitis Treatment Market Report 2025

The alcoholic hepatitis treatment market size has grown strongly in recent years. It will grow from $3.2 billion in 2024 to $3.44 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to high prevalence of alcohol abuse, increased awareness and diagnostics, government initiatives on alcoholism, increased healthcare expenditure, public health campaigns.

The alcoholic hepatitis treatment market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to emerging therapies and drug pipeline, precision medicine approaches, growing understanding of disease pathogenesis, increasing focus on liver health, public health policies addressing alcohol abuse. Major trends in the forecast period include personalized medicine approaches, liver transplantation trends, telemedicine and remote monitoring, collaborative research initiatives, innovative drug solutions.

The rising incidence of liver diseases related to alcohol consumption is anticipated to drive the growth of the alcoholic hepatitis treatment market in the future. Alcoholic liver disease results from damage to the liver's functions, which include filtering blood and producing bile for digestion. Alcoholic hepatitis treatment aims to address liver inflammation in some patients with this condition. Those with severe alcoholic hepatitis may require hospitalization for therapy. For example, in April 2024, data published by the Office for Health Improvement and Disparities, a UK government unit, revealed that there were 10,593 premature deaths from liver disease in 2022, including 6,664 males and 3,929 females. Additionally, the financial year ending in 2023 recorded 85,665 hospital admissions for liver disease in England, translating to a rate of 155.2 per 100,000 population, with 27,085 admissions specifically for alcoholic liver disease, which corresponds to a rate of 49.4 per 100,000 population. Therefore, the rising prevalence of alcohol-related liver diseases is propelling the growth of the alcoholic hepatitis treatment market.

The increasing emphasis on personalized medicine is expected to further boost the growth of the alcoholic hepatitis treatment market. Personalized medicine is a groundbreaking approach to medical treatment and healthcare that considers individual variations in patients' genes, environments, and lifestyles. This approach enables customized treatment plans, identification of susceptibility factors, optimization of medication selection, tailored therapies, individualized risk assessment, and a reduction in adverse effects, ultimately enhancing patient engagement and compliance with treatment plans. For instance, in February 2023, a report from the Personalized Medicine Coalition (PMC), a US-based non-profit organization, indicated that personalized medicines represented 35% of newly approved New Molecular Entities (NMEs) in 2021, with 12 new approvals in 2022, maintaining a consistent share of at least 25% of new drug approvals over the past eight years - a significant rise from under 10% a decade ago. Therefore, the growing focus on personalized medicine is driving the growth of the alcoholic hepatitis treatment market.

Product innovation stands as a prominent and increasingly adopted trend within the alcoholic hepatitis treatment market. Companies engaged in this sector are placing significant emphasis on pioneering new products to maintain their competitive edge. An illustrative example is the July 2022 release by Roche Holding AG of the Elecsys HCV Duo, a groundbreaking dual antibody and antigen diagnostic test for hepatitis C virus (HCV). This innovative test enables independent and simultaneous detection of HCV antigen and antibody status using a single human plasma or serum sample. It aids in identifying patients in recovery or exhibiting chronic infection symptoms that might lead to conditions such as liver cancer or early-stage infections. The early manifestation of HCV's core antigen during infection, utilized as an indicator of ongoing viral replication, enables physicians to diagnose active HCV at an earlier stage compared to using solely antibody assays, enhancing diagnostic capabilities.

Prominent entities in the alcoholic hepatitis treatment market are channeling their efforts towards product development, specifically focusing on immunoassays, as a strategic driver for revenue generation. Immunoassays represent a type of biochemical testing method leveraging antibodies' specific binding to antigens to detect and quantify the presence or concentration of a target molecule (analyte) in a sample. For instance, in November 2023, F. Hoffmann-La Roche Ltd. unveiled Elecsys HBeAg quant, an immunoassay designed to measure hepatitis B e antigen (HBeAg) levels in human serum and plasma in both qualitative and quantitative formats. It serves as a predictive tool for chronic active hepatitis and an early indicator of acute hepatitis B infection. This test aids in diagnosing and monitoring individuals with hepatitis B virus infection when complemented with supplementary laboratory findings and clinical data. The Elecsys HBeAg quant, compatible with Roche's Cobas e analyzers, is intended for use with samples from patients with known positive results as well as those with an undetermined HBeAg status.

In October 2022, the France-based biotechnology company Genfit completed the acquisition of Versantis AG for an undisclosed amount. This strategic move enhances GENFIT's leadership position in acute-on-chronic liver failure (ACLF) and significantly broadens its pipeline. The acquisition brings valuable assets to GENFIT's portfolio, including VS-01-ACLF, a Phase 2-ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program targeting urea cycle disorder (UCD), and VS-02-HE, an early-stage program focusing on hepatic encephalopathy (HE). Versantis AG, based in Switzerland, is a biotech company specializing in the development of therapeutics for hepatitis and alcohol-related liver diseases.

Major companies operating in the alcoholic hepatitis treatment market include AbbVie Inc., Gilead Sciences Inc., Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, GlaxoSmithKline plc, AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Novartis AG, Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Boehringer Ingelheim International GmbH, Mallinckrodt Pharmaceuticals, Intercept Pharmaceuticals Inc., Madrigal Pharmaceuticals, Inc., Conatus Pharmaceuticals Inc., DURECT Corporation, Viking Therapeutics Inc., CymaBay Therapeutics Inc., Genfit SA, BioVie Inc., Akero Therapeutics Inc., Zydus Cadila, Dr. Reddy’s Laboratories Ltd.

North America was the largest region in the alcoholic hepatitis treatment market in 2024. It is expected to be the fastest-growing region in the forecast period. The regions covered in the alcoholic hepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alcoholic hepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Alcoholic hepatitis treatment involves interventions aimed at promoting abstinence from alcohol and addressing the symptoms of liver damage. The therapeutic approach to alcoholic hepatitis focuses on the cessation of alcohol consumption and the administration of medications to alleviate liver-related symptoms.

The primary modalities of treatment for alcoholic hepatitis include pharmaceutical interventions and stem cell therapy. Pharmaceutical treatment entails the use of medications, excluding food, to prevent, detect, treat, or alleviate the symptoms of diseases or abnormal conditions. Drug classes such as corticosteroids, hemorheologic agents, monoclonal antibodies, anabolic steroids, and others are administered through oral and injectable routes. These treatments are typically provided by healthcare facilities, clinics, and private treatment centers.

The alcoholic hepatitis treatment market research report is one of a series of new reports that provides alcoholic hepatitis treatment market statistics, including alcoholic hepatitis treatment industry global market size, regional shares, competitors with an alcoholic hepatitis treatment market share, detailed alcoholic hepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the alcoholic hepatitis treatment industry. This alcoholic hepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alcoholic hepatitis treatment market consists of revenues earned by entities by providing infection surveillance, ulcer prophylaxis, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The alcoholic hepatitis treatment market also includes sales of anti-inflammatory medication such as steroids, pentoxifylline, and glucocorticoids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.